Actos (Pioglitazone) Pre-Surgery Hold Window: Clinical Guide

What the Actos label does say

The boxed warning is congestive heart failure. Thiazolidinediones, including Actos, cause or exacerbate heart failure in some patients. The Actos label says to monitor for excessive rapid weight gain, shortness of breath, and edema after starting Actos or increasing its dose. If heart failure develops, the label says it should be managed according to current standards of care, and discontinuation or dose reduction must be considered [1].

Actos is not recommended in patients with symptomatic heart failure. Starting it in patients with established NYHA class III or IV heart failure is contraindicated [1].

How large is the heart failure signal?

In PROactive, 5,238 adults with type 2 diabetes and macrovascular disease took pioglitazone titrated from 15 mg to 45 mg or placebo for a mean of 34.5 months. Hospitalized heart failure occurred in 5.7% (149/2,605) on pioglitazone and 4.1% (108/2,633) on placebo; fatal heart failure occurred in 1.0% vs 0.8% [1]. Edema was 26.7% vs 15.3% [1].

Does kidney function change the label's dosing?

The Actos label says no dose adjustment is needed for renal impairment [1]. It lists a pioglitazone half-life of 3 to 7 hours and an active metabolite half-life of 16 to 24 hours [1].

When does pioglitazone cause low blood sugar?

Pioglitazone is not an insulin secretagogue [1]. The label ties hypoglycemia to combination with insulin or insulin secretagogues such as sulfonylureas. If hypoglycemia occurs with a sulfonylurea, the label says to lower the sulfonylurea; with insulin, lower insulin by 10% to 25% [1]. In a 16-week add-on to insulin trial, hypoglycemia was 15.4% with Actos 30 mg vs 4.8% with placebo, and edema was 17.6% vs 7.0% [1].

Which drug interactions matter?

Gemfibrozil, a strong CYP2C8 inhibitor, raises pioglitazone exposure about 3-fold; the Actos label limits the dose to 15 mg daily with gemfibrozil or other strong CYP2C8 inhibitors [1]. Rifampin, a CYP2C8 inducer, may significantly lower pioglitazone exposure, and the label says diabetes treatment may need adjustment without exceeding 45 mg daily [1]. Topiramate lowers exposure to pioglitazone and its active metabolites; the clinical relevance is unknown, and the label says to monitor glycemic control [1]. In a single-dose study of 12 healthy volunteers, itraconazole did not significantly change pioglitazone pharmacokinetics [2].

What about restarting?

The Actos dosing instructions give no post-surgery restart schedule [1]. The label's guidance is the same as at any start or dose increase: monitor for fluid retention and signs of heart failure [1].